Idogen publishes interim report for 1 January – 31 December 2022
Idogen AB's interim report for January to December 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/
Fourth quarter (October-December 2022)
• Other operating income amounted to KSEK 256 (3,335)
• Operating loss was KSEK -11,759 (-13,552)
• Loss for the quarter totaled KSEK -11,465 (-13,529)
• Cash flow from operating activities was KSEK -12,591 (-15,074)
• Loss per share before dilution was SEK -0.16 (-0.61). Loss per share after dilution was SEK -0.16 (-0.61)
• The proposed dividend is SEK 0.00/share (0.00)
Period (January-December 2022)
• Other operating income amounted to KSEK 414 (13,915)
• Operating loss was KSEK -47,972 (-38,965)
• Loss for the quarter totaled KSEK -47,750 (-38,854)
• Cash flow from operating activities was KSEK -50,703 (-40,190)
• Loss per share before dilution was SEK -0.76 (-2.02). Loss per share after dilution was SEK -0.76 (-2.02)
Significant events in the fourth quarter
• First patient is included in Norway.
- Idogen's Idogen sharpens focus on its IDO 8 program, pauses the IDO T and IDO programs and lowers operating expenditure.
• Idogen receives after exercise of warrants 280 KSEK before costs.
• First patient enters Idogen’s hemophilia study under the IDO 8 program.
• EU to disburse the remaining of the Horizon 2020 grant.
• Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors.
• The board of Idogen propose a rights issue at up to 38 MSEK net after cost.
• Idogen invites for an extra shareholder meeting 13 December
Significant events in the period
• Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.
• Idogens presented the company’s tolerogenic cell therapy platform at the 5th Antigen-Specific Immune
Tolerance Summit.
• Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from May 15.
• Idogen’s rights issue raise MSEK 41 after issue costs.
• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study
for IDO 8.
• Idogen’s rights issue raise MSEK 41 after issue costs.
• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.
• Idogen strengthens the organization with key competencies for the clinical development phase.
• Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.
• Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study with the IDO 8-program.
• An extraordinary general meeting of shareholders on September 6 elected Joakim Söderström as new
chairman and Niklas Wallet as a new member of the Board of Directors.
• Christina Herder is appointed acting CEO after Anders Karlsson.
Significant events after the end of the period
• New issue gives proceed of net 5.3 MSEK after costs.
• Idogen invited by GJCF to participate in their 3rd Summit for NMOSD Tolerization
• Idogen will pause the clinical trial in the IDO 8 program as the company currently do not have sufficient capital
• No other significant events occurred after the end of the period that affected the results or financial position.
For further information, please contact:
Christina Herder, Acting CEO, Idogen AB
Tel: +46 70 374 71 56
E-mail: christina.herder@idogen.com
Certified Adviser:
Vator Securities AB
The information was submitted for publication, through the agency of the contact persons set out above, on February 24, 2023 at 12:04 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.